789 West Pender Street
Suite 810
Vancouver, BC V6C 1H2
Canada
720-277-9879
https://www.mydecine.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 3
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. David Joshua Bartch | Co-Founder, CEO, President & Chairman of the Board | 444,52k | S.O. | 1988 |
Mr. Robert Roscow M.A. | Co-Founder, Chief Scientific Officer & Director | 455,31k | S.O. | S.O. |
Mr. Damon Michaels | Co-Founder & COO | 455,31k | S.O. | S.O. |
Mr. John Charles Ross CA, CPA, M.B.A. | CFO & Corporate Secretary | 9,2k | S.O. | 1958 |
Mr. Sanford M. Stein | Chief Compliance Officer & General Counsel | 317,36k | S.O. | S.O. |
Dr. Rakesh Jetly FRCPC, M.D. | Chief Medical Officer | 271,2k | S.O. | S.O. |
Morgan Kervitsky | Director of Marketing | S.O. | S.O. | S.O. |
Mr. Michel Rudolphie | President of the European Operations | S.O. | S.O. | S.O. |
Mr. William Cook | Interim CEO & Technical Director of Mindleap Health Inc. | S.O. | S.O. | S.O. |
Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
L’ISS Governance QualityScore de Mydecine Innovations Group Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..